07:00 , Jun 7, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer BMX non-receptor tyrosine kinase (BMX; ETK) Mouse studies suggest inhibiting BMX...
07:00 , Apr 21, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer BMX non-receptor tyrosine kinase (BMX; ETK) In vitro and mouse studies suggest that decreasing glioblastoma...
07:00 , Apr 3, 2000 |  BioCentury  |  Finance

Pass the ladle

Pass the ladle Company 3/24 mkt cap (US$M) Cash (000s) 12/31 cash unless noted Amgen (AMGN) $55,654.3 $1,333,000 PE Bio (PEB) $20,580.0 $295,526 Immunex(IMNX) $11,896.3 $7,098,000 Medimmune (MEDI) $11,814.1 $270,394 Biogen (BGEN) $11,628.3 $654,539 Elan...
07:00 , Oct 25, 1999 |  BC Week In Review  |  Clinical News

Synvisc modified natural hyaluronan regulatory update

BMX said the U.K. National Health Service will reimburse Synvisc as a prescription to treat osteoarthritis of the knee, allowing general practitioners and primary care physicians to prescribe Synvisc without referrals to a specialist. Biomatrix...